通策医疗（600763）2月9日主力资金净卖出2438.98万元

Core Viewpoint - Tongce Medical (600763) experienced a slight decline in stock price, closing at 49.06 yuan, down 1.33% as of February 9, 2026, with a trading volume of 128,800 hands and a total transaction amount of 633 million yuan [1] Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year; net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year; and net profit excluding non-recurring items was 509 million yuan, rising 3.09% year-on-year [3] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34%; net profit attributable to shareholders for the quarter was 192 million yuan, up 2.31% year-on-year; and net profit excluding non-recurring items was also 192 million yuan, increasing by 1.85% year-on-year [3] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is 41.69% [3] Market Activity - On February 9, 2026, the net outflow of main funds was 24.39 million yuan, accounting for 3.85% of the total transaction amount, while retail investors saw a net inflow of 12.62 million yuan, representing 2.0% of the total transaction amount [1] - The financing data indicates that on the same day, financing purchases amounted to 50.86 million yuan, while financing repayments totaled 62.15 million yuan, resulting in a net repayment of 11.29 million yuan [2] - The stock has received three buy ratings from institutions in the last 90 days [4]